Description
Europe precision medicine Market
Precision medicine is reshaping the healthcare sector in Europe. Europe is the second largest revenue-generating region for the precision medicine market. The growth of the precision medicine market in European countries is mainly due to the adoption of gene therapy and an ageing population, among others. European countries like The U.K and Germany are experiencing growth in the region due to investments in research and development, along with rising incidence of chronic ailments. According to Netscribes, the European precision medicine market is projected to expand at a compound annual growth rate (CAGR) of 13.40%, leading to a revenue of USD 29.93 Bn by 2023.
Technological progress in big data analytics will help create opportunities for the precision medicine market. Diagnostic tool companies will also generate demand for the precision medicine market in the region. Due to the number of precision medicine solutions and medications offered in Germany, it is expected to have an important share in the region.
The European precision medicine market is classified into three primary segments: based on ecosystem players: pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies; based on therapeutics: cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases; and based on technology: big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics.
The cancer therapeutics segment is expected to exhibit the highest growth rate in this region. This is because rising incidence of cancer will create demand for its treatment. In the long run, genetic differentiation will increase demand for tailored cancer therapeutics. In the technology segment, big data analytics is expected to register a high growth rate through the forecast period of 2018-2023.
Key growth factors
Rising incidences of Alzheimers disease and other neurological disorders, along with increased awareness to prevent them, will create demand for the precision medicine market. An increase in the use of targeted therapies and medicines will help the growth of pharmaceutical and biotech companies in Europe. Companion diagnostics providers will improve the data collection, which will in turn, boost the precision medicine market
Threats and key players
Rising healthcare costs in the European region is one of the challenges for the precision medicine market, which will restrict its adoption in the region. Concerns regarding privacy and the security of personal data, are expected to adversely affect the growth of precision medicine market in Europe.
The major players operating in the Europe precision medicine market are Almac Group, GE healthcare, Novartis, etc.
Whats covered in the report?
1. Overview of the Europe precision medicine market.
2. Market drivers and challenges in the Europe precision medicine market.
3. Market trends in the Europe precision medicine market.
4. Historical, current and forecasted market size data for the North America precision medicine market segmentation by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies) by revenue (USD Bn).
5. Historical, current and forecasted market size data for the North America precision medicine market segmentation by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases) by revenue (USD Bn).
6. Historical, current and forecasted market size data for the North America precision medicine market segmentation by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics) – by revenue (USD Bn).
7. Historical, current and forecasted country-wise (U.S. and Canada) market size data (USD Bn) for the North America precision medicine market and its segmentations by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies), by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases), and by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics).
8. Analysis of the competitive landscape and profiles of major companies operating in the market.
Why buy?
1. Unders
Table of Contents
Chapter 1: Executive summary
1.1. Market scope and segmentation
1.2. Key questions answered
1.3. Executive summary
Chapter 2: Europe precision medicine market – overview
2.1. Europe market overview – market trends, drivers and challenges
2.2. Value chain analysis
2.3. Porter’s Five Forces analysis
2.4. Market size – by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
2.4. a. Revenue from pharmaceuticals and biotech companies – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.4. b. Revenue from clinical laboratories – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.4. c. Revenue from diagnostic companies – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.4. d. Revenue from healthcare IT specialists/big data companies – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. Market size- by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
2.5. a. Revenue from cancer – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. b. Revenue from cardiovascular- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. c. Revenue from central nervous system – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. d. Revenue from psychiatric disorder – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. e. Revenue from infectious diseases – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. Market size- by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
2.6. a. Revenue from big data analytics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. b. Revenue from bioinformatics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Revenue from gene sequencing – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Revenue from pharmacogenomics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Revenue from companion diagnostics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
Chapter 3: Europe precision medicine market- by countries
3.1. The U.K.
3.1.1. Market overview- market trends, drivers and challenges
3.1.2. Market size- by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
3.1.2. a. Revenue from pharmaceuticals and biotech companies – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.2. b. Revenue from clinical laboratories – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.2. c. Revenue from diagnostic companies – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.2. d. Revenue from healthcare IT specialists/big data companies – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. Market size- By therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
3.1.3. a. Revenue from cancer – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. b. Revenue from cardiovascular – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. c. Revenue from psychiatric disorder – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. d. Revenue from infectious diseases – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. Market size- By technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
3.1.4. a. Revenue from big data analytics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. b. Revenue from bioinformatics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. c. Revenue from gene sequencing – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. c. Revenue from pharmacogenomics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. c. Revenue from companion diagnostics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. Germany
3.2.1. Market overview- market trends, drivers and challenges
3.2.2. Market size- by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
3.2.2. a. Revenue from pharmaceuticals and biotech companies – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.2. b. Revenue from clinical laboratories – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.2. c. Revenue from diagnostic companies – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.2. d. Revenue from healthcare IT specialists/big data companies – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. Market size- By therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
3.2.3. a. Revenue from cancer – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. b. Revenue from cardiovascular – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. c. Revenue from psychiatric disorder – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. d. Revenue from infectious diseases – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. Market size- By technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
3.2.4. a. Revenue from big data analytics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. b. Revenue from bioinformatics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. c. Revenue from gene sequencing – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. c. Revenue from pharmacogenomics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. c. Revenue from companion diagnostics – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
Chapter 4: Competitive landscape
4.1. Abbott Laboratories
4.1.a. Company snapshot
4.1.b. Product offerings
4.1.c. Growth strategies
4.1.d. Initiatives
4.1.e. Geographical presence
4.1.f. Key numbers
4.2. GE Healthcare
4.2.a. Company snapshot
4.2.b. Product offerings
4.2.c. Growth strategies
4.2.d. Initiatives
4.2.e. Geographical presence
4.2.f. Key numbers
4.3. GlaxoSmithKline (GSK)
4.3.a. Company snapshot
4.3.b. Product offerings
4.3.c. Growth strategies
4.3.d. Initiatives
4.3.e. Geographical presence
4.3.f. Key numbers
4.4. Johnson & Johnson
4.4.a. Company snapshot
4.4.b. Product offerings
4.4.c. Growth strategies
4.4.d. Initiatives
4.4.e. Geographical presence
4.4.f. Key numbers
4.5. Pfizer
4.5.a. Company snapshot
4.5.b. Product offerings
4.5.c. Growth strategies
4.5.d. Initiatives
4.5.e. Geographical presence
4.5.f. Key numbers
4.6. Randox Laboratories
4.6.a. Company snapshot
4.6.b. Product offerings
4.6.c. Growth strategies
4.6.d. Initiatives
4.6.e. Geographical presence
4.6.f. Key numbers
4.7. Almac Group
4.7.a. Company snapshot
4.7.b. Product offerings
4.7.c. Growth strategies
4.7.d. Initiatives
4.7.e. Geographical presence
4.7.f. Key numbers
4.8. Novartis AG
4.8.a. Company snapshot
4.8.b. Product offerings
4.8.c. Growth strategies
4.8.d. Initiatives
4.8.e. Geographical presence
4.8.f. Key numbers
4.9. Teva Pharmaceuticals Limited
4.9.a. Company snapshot
4.9.b. Product offerings
4.9.c. Growth strategies
4.9.d. Initiatives
4.9.e. Geographical presence
4.9.f. Key numbers
4.10. Quest Diagnostics
4.10.a. Company snapshot
4.10.b. Product offerings
4.10.c. Growth strategies
4.10.d. Initiatives
4.10.e. Geographical presence
4.10.f. Key numbers
Chapter 5: Conclusion
Chapter 6: Appendix
6.1. List of tables
6.2. Research methodology
6.3. Assumptions
6.4. About Netscribes Inc.
Note: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research
